Del-desiran not checked
Avidity Biosciences, Inc. · AOC 1001
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Del-desiran will be administered by intravenous (IV) infusion.”In the company’s words, NCT07008469 on ClinicalTrials.gov
- Tested for
- Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
- Main trialPhase 3
- “A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1”In the company’s words, NCT07008469 on ClinicalTrials.gov
- Other names
- AOC 1001
Other drugs for Myotonic Dystrophy Type 1
- TideglusibAMO Pharma Limited · Phase 2/3
- Mexiletine granulesLupin Ltd. · Phase 3
- Zeleciment basivarsenDyne Therapeutics · Phase 3
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- SRP-1003Sarepta Therapeutics, Inc. · Phase 1/2
Coming up1
- Oct 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Enrolling by invitation | Oct 2030 | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | |
| Phase 3Completed | 23 Jul 2026 | Global Study of Del-desiran for the Treatment of DM1 | |
| Phase 2Completed | 5 Sep 2025 | Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | |
| Phase 1/2Completed | 14 Feb 2023 | Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026